A number of other research analysts also recently weighed in on the stock. ValuEngine upgraded shares of Audentes Therapeutics from a hold rating to a buy rating in a research report on Friday, June 1st. Mizuho reiterated a hold rating and issued a $38.00 price objective on shares of Audentes Therapeutics in a research report on Monday, May 21st. HC Wainwright set a $40.00 price objective on shares of Audentes Therapeutics and gave the stock a buy rating in a research report on Thursday, May 17th. William Blair reiterated a buy rating on shares of Audentes Therapeutics in a research report on Thursday, May 17th. Finally, Wedbush upped their price target on shares of Audentes Therapeutics from $49.00 to $56.00 and gave the stock an outperform rating in a research report on Thursday, May 10th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $35.80.
Shares of Audentes Therapeutics stock traded down $0.20 during trading hours on Wednesday, reaching $36.02. The stock had a trading volume of 201,796 shares, compared to its average volume of 302,382. Audentes Therapeutics has a twelve month low of $16.46 and a twelve month high of $46.18.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.07). sell-side analysts predict that Audentes Therapeutics will post -3.39 earnings per share for the current year.
In related news, CEO Matthew R. Patterson sold 71,048 shares of the company’s stock in a transaction dated Thursday, July 5th. The shares were sold at an average price of $39.55, for a total transaction of $2,809,948.40. Following the completion of the transaction, the chief executive officer now owns 19,599 shares in the company, valued at approximately $775,140.45. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP David Nagler sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $45.29, for a total transaction of $226,450.00. Following the transaction, the senior vice president now owns 4,700 shares of the company’s stock, valued at approximately $212,863. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,794 shares of company stock valued at $6,960,349. Insiders own 6.60% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Federated Investors Inc. PA acquired a new stake in Audentes Therapeutics in the 2nd quarter valued at about $5,084,000. JBF Capital Inc. raised its holdings in Audentes Therapeutics by 46.9% in the 2nd quarter. JBF Capital Inc. now owns 31,300 shares of the biotechnology company’s stock valued at $1,196,000 after acquiring an additional 10,000 shares during the last quarter. BlackRock Inc. raised its holdings in Audentes Therapeutics by 25.4% in the 2nd quarter. BlackRock Inc. now owns 2,458,171 shares of the biotechnology company’s stock valued at $93,925,000 after acquiring an additional 497,767 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Audentes Therapeutics by 48.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 67,660 shares of the biotechnology company’s stock valued at $2,586,000 after acquiring an additional 22,063 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Audentes Therapeutics in the 2nd quarter valued at about $231,000. Institutional investors own 94.27% of the company’s stock.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
See Also: Investing in Dividend Stocks
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.